PIROXICAM-SAVIOUR IN COVID-19

OMKAR KALIDASRAO CHOUDHARI; DISHA SATYA; PRIYANKA SONI; NAVEEN GUPTA

doi:10.22159/ijcpr.2025v17i6.7058

Authors

OMKAR KALIDASRAO CHOUDHARI Department of Clinical Hematology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
DISHA SATYA Department of Clinical Hematology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India https://orcid.org/0009-0001-7251-3441
PRIYANKA SONI Department of Clinical Hematology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
NAVEEN GUPTA Department of Clinical Hematology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India

DOI:

https://doi.org/10.22159/ijcpr.2025v17i6.7058

Keywords:

COVID-19, Cytokine storm, Piroxicam

Abstract

The pandemic of Coronavirus Disease-2019 (COVID-19) still remains a threat. Its treatment led to the repositioning of many drugs. Piroxicam is one of the non-steroidal anti-inflammatory drugs, which inhibits prostaglandin synthesis and has antiviral activity against NRC-03-nhCoV. Lymphopenia is one of the severity indicators in COVID-19. Cytokine storm is responsible for significant morbidity and mortality in COVID-19. Piroxicam has been shown to induce bone marrow Lymphopoiesis and inhibit Tumour necrosis factor alpha (TNF-α), TNF-γ, actively involved in the cytokine storm.

Downloads

Download data is not yet available.

References

1. Chowdhury AT, Shahbaz M, Karim M, Islam J, Dan G, He S. A comparative study on ivermectin, doxycycline and hydroxychloroquine azithromycin therapy on COVID-19 patients. EJMO. 2021;5(1):63-70. doi: 10.14744/ejmo.2021.16263.

2. World Health Organization. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. Available from: https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(NSAIDs)-in-patients-with-Covid-19. [Last accessed on 10 Jul 2023].

3. World Health Organization. WHO updates clinical care guidance with corticosteroid recommendations. Available from: https://www.who.int/news-room/feature-stories/detail/who-updates-clinical-care-guidance-with-corticosteroid-recommendations. [Last accessed on 10 Jul 2023].

4. World Health Organization. WHO COVID-19 dashboard. Available from: Https://data.who.int/dashboards/covid19/cases. [Last accessed on 10 Jul 2023].

5. All India Institute of Medical Sciences (AIIMS). Available from: https://covid.aiims.edu/clinical-guidance-for-management-of-adult-covid-19-patients/. [Last accessed on 10 Jul 2023].

6. World Health Organization. WHO COVID-19 solidarity therapeutics trial. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. [Last accessed on 10 Jul 2023].

7. World Health Organization. Diagnostics therapeutics, vaccine readiness and other health products for COVID-19. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1. [Last accessed on 10 Jul 2023].

8. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42. doi: 10.1016/j.cytogfr.2020.04.002, PMID 32360420.

9. Mohammed Y, Narayana S, Arun H. A comparative study of efficacy and safety of piroxicam and naproxen in the management of pain in osteoarthritis of the knee. J Nat Sci Biol Med. 2018;9(2):178-82. doi: 10.4103/jnsbm.JNSBM_154_17.

10. Mostafa A, Kandeil A, A MM Elshaier Y, Kutkat O, Moatasim Y, Rashad AA. FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2. Pharmaceuticals (Basel). 2020;13(12):443. doi: 10.3390/ph13120443, PMID 33291642.

11. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020;8:36. doi: 10.1186/s40560-020-00453-4, PMID 32483488.

12. Hassanein NM, Hasan WA, Hamed MR. Effects of diclofenac piroxicam and alpha-tocopherol on monoaminelymphopoietic interfacing in mice. Arzneim Forsch. 2004;54(12):847-56. doi: 10.1055/s-0031-1297040, PMID 15646369.

13. Rosenstein ED, Kunicka J, Kramer N, Goldstein G. Modification of cytokine production by piroxicam. J Rheumatol. 1994;21(5):901-4. PMID 8064732.